Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 6, 2006

Bayer Licenses Brenda-Amenda Database for Target Research

  • Bayer HealthCare gained access to Biobase’s enzyme and metabolism research database, according to a license agreement between the two companies. The Brenda-Amenda database summarizes more than 50 years worth of research in this field. Bayer Healthcare will be using the database for target-based research related to cardiovascular disease.

    The new text-mining based Amenda module expands Brenda's enzyme-related reference content five-fold by means of structured access to organism-specific enzyme information, such as statements about tissue affiliation or subcellular localization, from 15 million PubMed articles.

    Brenda-Amenda is a relational database that contains manually-curated biochemical and molecular information about more than 83,000 enzymes from 9,800 organisms. To date, Brenda-Amenda contains 500,000 enzyme-ligand correlations, including more than 46,000 different chemical compounds that act as ligands and 34,500 ligand structures.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »